Glucose and methionine uptake and proliferative activity in meningiomas

Neurological Research

Volumn 21, Issue 7, 1999, Pages 640-644

  Iuchi, Toshihiko ^a   Iwadate, Yasuo ^b   Namba, Hiroki ^a   Osato, Katsunobu ^a   Saeki, Naokatsu ^b   Yamaura, Akira ^b   Uchida, Yoshitaka ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AgNOR; Ki 67; Meningioma; 11C MET PET; 18F FDG PET

Indexed keywords

DNA; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; KI 67 ANTIGEN; METHIONINE C 11; PROTEIN;

ARTICLE; CHROMOSOME NOR; CLINICAL ARTICLE; HUMAN; MENINGIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEIN SYNTHESIS; TUMOR BIOPSY;

EID: 0032754652     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1080/01616412.1999.11740989     Document Type: Article

References (33)

1. Yääskeläinen J, Haltia M, Laasonen E, Wahlström T, Valtonen S. The growth rate of intracranial meningiomas and its relation to histology. Surg Neurol 1985; 24: 165-172
2. Allegranza A, Girlande S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, et al. Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch (Patholo Anat) 1991; 419: 417-423
3. Crocker J, Boldy DAR, Egan MJ. How should we count AgNORs? Proposals for a standardized approach. J Pathol 1989; 158: 185-188
4. Hoshino T, Nagashima T, Nurovic J, Wilson CB, Davis RL. Proliferative potential of human meningiomas of the brain, a cell kinetics study with bromodeoxyuridine. Cancer 1986; 58: 1466-1472
5. Hoshino T, Wilson CB. Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer 1979; 44: 956-962
6. Khoshyomn S, Maier H, Morimura T, Kitz K, Budka H. Immunostaining for proliferating cell nuclear antigen: Its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 1993; 86: 582-589
7. Maier H, Öfner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: Three histopathological subtypes of clinical relevance. J Neurosurg 1992; 77: 616-623
8. Ng IO, Na J, Lai EC, Fan ST, Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995; 104: 313-318
9. Okada M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer 1994; 74: 3176-3189
10. Rüschoff J, Plate K, Bittinger A, Thoma C. Nucleolar organizer regions (NORs). Basic concepts and practical application in tumor pathology. Path Res Pract 1989; 185: 878-885
11. Sasaki A, Naganuma H, Kimura R, Isoe S, Nakano S, Nukui H, Suzuki K, Kawaoi A. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumors in paraffin embedded sections. Acta Neurochir 1992; 117: 148-181
12. Shiraishi T, Tabuchi K, Mineta T, Momozaki N, Takagi M. Nucleolar organizer regions in various human brain tumors. J Neurosurg 1991; 74: 979-984
13. Zimmer C, Gottschalk J, Cervos-Navarro J, Martin H, Beil M, Jautzke G. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas. Pathol Res Pract 1992; 188: 951-958
14. Alavi JB, Alava A, Chawluk J, Kushner M, Powe J, Mickey W, Reivich M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-1078
15. 18F fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329
16. Patronas NJ, DiChiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816-822
17. de Wolde H, Pruim J, Mastik MF, Koudstaal J, Molenaar WM. Proliferative activity in human brain tumors: Comparison of histopathology and L-[1-11C]Tyrosine PET. J Nucl Med 1997; 38: 1369-1374
18. Goldman S, Levivier M, Pirotte B, Brucher J-M, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J. Regional methionine and glucose uptake in high-grade gliomas: A comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38: 1459-1462
19. 11C-methionine. AJNR 1996; 17: 345-353
20. Howell WN, Black DA. Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: A 1-step method. Experientia 1980; 36: 1014-1015
21. 11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med 1988; 29: 1419-1427
22. Lakher MB, Wurtman RJ. Molecular composition of the phosphatidylcholines produced by the phospholipid methylation pathway in rat brain in vivo. Biochem J 1987; 244: 325-330
23. Tisdale MJ. Changes in tRNA methyltransferase activity and cellular S-adenosylmethionine content following methionine deprivation. Biochem Biophys Acta 1980; 609: 296-305
24. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda M. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissue be measured in vivo? J Nucl Med 1993; 34: 1936-1943
25. 11C]-tyrosine PET for visualisation of brain tumors and quantitation of the protein synthesis rate. Radiology 1995; 197: 221-226
26. Dorward NL, Alberti O, Velani B, Gerritsen FA, Harkness WFJ, Kitchen ND, Thomas DGT. Postimaging brain distortion: Magnitude, correlates, and impact on neuronavigation. J Neurosurg 1998; 88: 656-662
27. Watanabe E, Watanabe T, Manaka S, Mayanagi Y, Takakura K. Three-dimensional digitizer (Neuronavigator): New equipment for computed tomography-guided stereotaxic surgery. Surg Neurol 1987; 27: 543-547
28. Allam A, Taghian A, Gioioso D, Duffy M, Suit HD. Intratumoral heterogeneity of malignant gliomas measured in vitro. Int J Radiat Oncol Biol Phys 1993; 27: 303-308
29. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labelling index. J Neuropathol Exp Neurol 1993; 52: 609-618
30. Paulus W, Pfeiffer J. Intratumoral histologic heterogeneity of gliomas. Cancer 1989; 64: 442-447
31. Siegers HP, Zuber P, Hamou MF, Melle GDV, Tribolet NDE. The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas. Br J Neurosurg 1989; 3: 101-108
32. Cremerius U, Bares R, Weis J, Sabri O, Mull M, Schhröder M, Gilsbach JM, Buell U. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med 1997; 38: 26-30
33. Di Chiro G, Hatazawa J, Kats DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology 1987; 164: 521-526